Quoin Pharmaceuticals Advances Targeted Radiotherapy Solutions for Cancer with Actinium Innovations

Actinium Pharmaceuticals Advances Targeted Radiotherapy Solutions for Cancer Treatment

Actinium Pharmaceuticals, Inc. is making significant strides in the development of targeted radiotherapies that address critical oncology challenges. The company focuses on its lead product candidate, ATNM-400, which is designed to target Ac-225 for the treatment of prostate cancer and non-small cell lung cancer (NSCLC). This innovative therapy aims to specifically target antigens associated with metastatic castration-resistant prostate cancer (mCRPC), a stage of prostate cancer known for its aggressive nature and poor survival rates. Recent preclinical studies reveal that ATNM-400 demonstrates superior efficacy compared to existing treatments such as enzalutamide (Xtandi®) and Pluvicto®, showcasing its potential to control tumors durably and effectively combat resistant forms of prostate cancer.

In the realm of NSCLC, ATNM-400 shows promising potential as well. The therapy outperforms conventional EGFR-targeting treatments, including osimertinib (TARGRISSO®), and has proven to create synergistic effects when combined with these therapies. This capability positions Actinium at the forefront of developing advanced cancer treatments, particularly for patients who have limited options due to resistance to current therapies. The promising results from preclinical data highlight the need for further exploration and clinical trials, reinforcing the company's commitment to enhancing patient outcomes in oncology.

Actinium Pharmaceuticals is also progressing with its other notable candidate, Actimab-A, which targets CD33 and is being developed as a backbone therapy for acute myeloid leukemia (AML). Actimab-A has demonstrated impressive activity in patients with relapsed and refractory AML, achieving high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity. This candidate is currently advancing towards a pivotal Phase 2/3 trial, indicating the potential for a breakthrough in AML treatment and further establishing Actinium's reputation in the field of hematologic malignancies.

In addition to its product development, Actinium collaborates with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA). This partnership aims to bolster the company’s research efforts and accelerate the development of its innovative therapies. The collaboration reflects Actinium's strategic approach to harnessing external expertise and resources, ultimately driving forward its mission to deliver effective cancer treatments that improve patient lives.